Merck, Keytruda and Neck Cancers
Merck expects oncology king Keytruda to face IRA 'price setting' process starting in 2026
Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. | The government price negotiations affecting Keytruda wouldn't take effect until 2028,
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
10hon MSN
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...
An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.
Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than 130 billion U.S. dollars in sales ...
Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...
Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback